LUCD - צמיחת הכנסות משנה לשנה ב-12 החודשים האחרונים Lucid Diagnostics, Inc

Lucid Diagnostics Inc. generates revenue by integrating early esophageal cancer detection tests into clinical protocols. Operations are limited to the US market, meaning geopolitical influence is restricted to rising logistics costs. The popularity of rapid testing methods is expanding the gastroenterologist customer base. The annual sales revenue trend over four quarters clearly demonstrates a trajectory where the value of 24.00 characterizes this level.
Lucid Diagnostics Inc (LUCD) - פילוחי מדדים ודוחות פיננסיים

This indicator is critical when stress-testing assets to determine the business life cycle phase and the maturity of its expansion. The metric measures the percentage change in revenue over the last twelve months relative to the previous year, while the year-over-year sales volume growth trajectory for TTM reflects the scaling efficiency of Lucid Diagnostics Inc. (LUCD) EsoGuard tests through clinic partnerships.